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Objectives: The 2005 International Health Regulations (IHR 2005) emphasized the impor-
tance of laboratory capacity to detect emerging diseases including novel influenza viruses.
To support IHR 2005 requirements and the need to enhance influenza laboratory surveil-
lance capacity, the Association of Public Health Laboratories (APHL) and the Centers for
Disease Control and Prevention (CDC) Influenza Division developed the International
Influenza Laboratory Capacity Review (Tool).
Study design: Data from 37 assessments were reviewed and analyzed to verify that the
quantitative analysis results accurately depicted a laboratory's capacity and capabilities.
Methods: Subject matter experts in influenza and laboratory practice used an iterative
approach to develop the Tool incorporating feedback and lessons learnt through piloting
and implementation. To systematically analyze assessment data, a quantitative frame-
work for analysis was added to the Tool.
Results: The review indicated that changes in scores consistently reflected enhanced or
decreased capacity. The review process also validated the utility of adding a quantitative
analysis component to the assessments and the benefit of establishing a baseline from
which to compare future assessments in a standardized way.
Conclusions: Use of the Tool has provided APHL, CDC and each assessed laboratory with a
standardized analysis of the laboratory's capacity. The information generated is used to
improve laboratory systems for laboratory testing and enhance influenza surveillance
globally. We describe the development of the Tool and lessons learnt.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P Solutions, Inc., 12054 North Shore Drive, Reston, VA 20190, USA. Tel.: þ1 262 510 1575.
(S.A. Muir-Paulik).
y Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
).
p u b l i c h e a l t h 1 3 0 ( 2 0 1 6 ) 7 2e7 7 73IntroductionAs a part of the World Health Organization (WHO) Global
Influenza Surveillance and Response System (GISRS), National
Influenza Centers (NICs) have monitored influenza for over 60
years.1 An integral part of the influenza surveillance system,
NICs detect, report and submit seasonal and emerging influ-
enza viruses to WHO Collaborating Centers for antigenic and
genetic characterization. These data are crucial for deter-
mining the Northern and Southern Hemisphere influenza
vaccine composition each year.2 Since 1952, WHO has recog-
nized 141 laboratories as NICs spanning 111 member
countries.1
Under articles five and thirteen of the 2005 WHO Interna-
tional Health Regulations (IHR 2005), countries are required to
‘develop, strengthen and maintain... the capacity to detect,
assess, notify and report events’ such as ‘public health risks…
and emergencies of international concern’.3 To support WHO
GISRS requirements and improve NIC capabilities to conduct
influenza surveillance, the Centers for Disease Control and
Prevention (CDC) Influenza Division supports epidemiology
and laboratory capacity building in over 40 countries through
the use of cooperative agreements.
While it is recognized that quality laboratory testing is
important for guiding public health decisions and policies1,2,4,5
there is, from a global perspective, limited information on
methods for measuring laboratory capacity including
measuring the impact of improving laboratory-based influ-
enza surveillance over time. AlthoughWHO established terms
of reference for NIC participation,1 standardized processes to
assess ongoing quality of influenza laboratories and fulfilment
of these terms is limited.
In response to the need for standardized capacity mea-
surement methods and to assist cooperative agreement and
partner countries to build laboratory capacity, the Association
of Public Health Laboratories (APHL), the CDC Influenza Divi-
sion and US public health laboratory (PHL) influenza subject
matter experts (SMEs) developed the International Influenza
Laboratory Capacity Review (Tool). Through a series of ques-
tions, focussing on specific categories of influenza laboratory
functions and practices, the Tool assists SMEs to assess lab-
oratory capacity of national influenza laboratories. Capacity in
this context refers to a laboratory's capability to test respira-
tory specimens for influenza utilizing standard methodolo-
gies, biosafety procedures, and quality assurance and quality
control methods and using the resulting data to contribute to
national and international influenza surveillance.
CDC and APHL collaborate to offer voluntary laboratory
capacity assessments for CDC cooperative agreement and
partner countries. Using the Tool, data are collected in a
standardized manner. The assessment feedback assists na-
tional influenza laboratories to establish, improve and/or
maintain influenza testing capabilities using internationally
accepted biosafety and quality control practices. It also helps
laboratories to attain or maintain NIC designation thereby
building and enhancing global influenza surveillance
capacity.
Following introduction and initial two year use of the
Tool, improvements were made and a process to apply aquantitative framework for analysis to key assessment
components was developed. This allows for a more system-
atic comparison of data from individual laboratories over
time. This paper details the development of the Tool and the
subsequent process to quantitatively analyze data collected
from laboratory assessments to characterize capacity across
different regions and globally.Methods
Developing the International Influenza Laboratory Capacity
Review
In 2009 representatives from PHLs and CDC, with expertise in
influenza laboratory methods and surveillance and famil-
iarity with WHO GISRIS influenza guidelines and laboratory
standards, created the Tool to assist in assessing interna-
tional laboratories' capacity for testing influenza specimens
and quality laboratory practices. As agreed upon by the SMEs,
through group discussion and majority consensus, the Tool
was developed to represent the essential laboratory func-
tions and practices of WHO NICs. The Tool was organized
into nine sections (general laboratory, virology laboratory,
molecular biology laboratory, influenza testing, laboratory
safety and biosafety, training, specimen handling, collection
and reporting, and quality assurance) and within each sec-
tion a series of questions prompts the assessor to evaluate
laboratory practice, identify strengths and develop recom-
mendations for improvement. Created in Microsoft Excel, the
modular design allows each section to be administered
independently and by different assessors. To test the Tool
and gain feedback on its usability and content, two pilot as-
sessments were conducted during 2009 in Europe and South
America. Utilizing the feedback from the pilot assessments,
individual questions were edited for clarity and the Tool was
finalized.
Tool revision and quantitative framework development
Assessors, influenza SMEs selected based on their educa-
tion, expertise, and previous work experience with influ-
enza laboratory diagnostics, completed thirty-seven
assessments between 2009 and 2011. Feedback was solicited
from the SMEs and it was revised to increase its usability
and prepare it for the development of a quantitative
framework. Individual questions were edited for clarity,
new questions were added to address gaps and questions
were reorganized into different categories to better reflect
typical laboratory operations. The modular design was
retained; however, the sections were updated and reordered
to reflect the changes (e.g. the influenza specimen testing
section was eliminated because those questions were
moved into other sections).
As part of the revision process, the Tool was compared to
theWHO Europe National Influenza Centre Laboratory Assessment
Tool (NIC-LAT),6 which was developed and piloted a year after
the 2009 APHL-CDC Tool. While there is considerable overlap,
the tools serve different functions; the NIC-LAT is used as a
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Tool was developed to guide CDC cooperative agreement
partners in laboratory improvements. The purpose of the
comparison was to align the tools as closely as possible by
identifying potential information gaps. For example, the NIC-
LAT includes a series of questions for identifying a labo-
ratory's quality assurance of reagents and supplies. In recog-
nition of the value of such questions, the same questions were
added to the Tool. Approximately 19 questions from the NIC-
LAT were identified for inclusion in the Tool.
To improve completeness of data collection, the answer
options were revised. The majority of ‘do not know’ and ‘not
applicable’ answer options were eliminated to ensure that
assessors probe laboratorians and note responses. Where
possible open-ended questions were converted to yes/no or
multiple choice to prevent non-answers which could not be
scored. However, in some instances, open-ended questions
needed to be retained to fully capture the identified practice.
For those questions guidelines to determine if a practice was
either ‘acceptable’ or required a ‘recommendation’ were
created to improve standardization. For example, the ques-
tion ‘Please provide a brief description of the laboratory's
protocol/algorithm for unsubtypable influenza A specimens’
was provided with the following guideline: ‘to be acceptable,
assessors should look to see if the algorithm includes: an
immediate alert to WHO and shipping the specimen/s within
one week to a WHO Collaborating Centre, H5 Reference labo-
ratory, or National Influenza Centre (NIC) and provision of
information to national authorities in a timely manner.’ As-
sessors are asked to include the reasoning for their response
and make specific recommendations for improvement as
appropriate.
To enhance on-going monitoring and capture individual
laboratory and collective progress over time, a framework to
quantify and analyze key assessment data was developed
through an iterative process in consultation with SMEs with
expertise in influenza laboratory methods and surveillance.
First, we identified questions that were most representative
and critical to influenza laboratory surveillance functions. The
Tool contains 271 questions, an equipment table (to document
the type and number of operational equipment in the labo-
ratory) and training table (to document the type and number
of trainings provided to, or attended by, laboratory staff). The
questions fall into two categories: informational (e.g. the lab-
oratory location, business hours) and capacity-related (e.g.
under normal operating conditions, how often are influenza
specimens cultured during peak influenza season). From the
271 questions and the two tables, 180 capacity-related ques-
tions were selected for possible inclusion in the quantitative
analysis. Fifteen SMEs ranked the 180 questions on a scale of
one to three based on their perceived relative importance to a
laboratory's quality and function. Using their rankings and a
1.5 cutoff value, 164 of the 180 questions were identified as
essential to include in the quantitative analysis.
We assigned the 164 questions to one of the eight cate-
gories below. Six categories mirrored the previous Tool mod-
ules and two new categories were added: (1) NIC Criteria and
(2) Biosafety in Microbiological and Biomedical Laboratories
(BMBL): NIC Criteria: NIC criteria as defined in the WHO document
Terms of Reference for National Influenza Centres7;
 Laboratory Management: laboratory management sys-
tems and procedures;
 Safety: laboratory security and safety, in particular, the
safe handling and containment of infectious microorgan-
isms and hazardous biological materials;
 BMBL: specifically focuses on biosafety practices as defined
by the BMBL manual (5th Edition)8;
 Quality Assurance & Quality Control: systems and
methods a laboratory employs to minimize errors and
measure the accuracy of influenza test results;
 Molecular Biology: molecular biology procedures and
techniques used in an influenza laboratory;
 Virology: virology procedures and techniques used in an
influenza laboratory;
 Specimen Handling, Collection and Reporting: influenza
specimen handling, collection and reporting;
 Equipment: equipment and reagents used for performing
influenza testing.
From the 164 questions, the SMEs each selected the top 50%
of the questions assigned to each category that, in their
opinion, wouldmost accurately serve tomeasure capacity and
are hallmarks of quality for that category. From this review,
111 questions were chosen for inclusion in the quantitative
framework.
SMEs in monitoring and evaluation were consulted to
review the process to date and provide input on assigning
points. Based on feedback from consultants, experienced
assessors and assessed laboratories, it was determined that
each selected question be considered equally important to
meeting minimum standards of good laboratory practice,
well-functioning influenza diagnostics and attaining or
maintaining NIC status. Additionally, the Tool was to be
used to define areas of strength and deficiency therefore
allowing countries to choose improvements based on their
priorities and resources. For these reasons, weighting was
not applied. Each answer option was assigned a point value
of one or zero (e.g. yes ¼ 1, no ¼ 0; acceptable ¼ 1,
recommendation ¼ 0). For questions with multiple answer
options, each answer option was counted as an individual
point. Due to the inclusion of questions with multiple parts,
the total points available (161) are greater than the actual
number of questions (Table 1). To minimize bias, the point
system is not visible to either the assessor or the labo-
ratorians conducting the assessment.
After the completion of an assessment, the data are
entered into the spreadsheet, the points for each category are
automatically summed, divided by the total number of points
available in the category and converted to a percentage. This
percentage is used to compare categories that have different
denominators. In this way, when displayed on a chart, a lab-
oratory's performance in each category is easily visualized.
Repeat assessments can be placed on the same chart so
changes in laboratory capacity may be tracked over time
(Fig. 1). Aggregate data can be used for reports (e.g. project
status updates and regional and global level reports) and to
identify gaps and training needs.
Fig. 1 e Laboratory assessmentse percentage performance
by capacity category, 2010 (firstTool) vs 2013 (revisedTool).A
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Concordance of the quantitative analysis systems
At the time the quantitative frameworkwas developed, thirty-
seven assessments had been completed using the first Tool.
To compare the capacity of laboratories between their first
assessments and subsequent assessments, a quantitative
framework was retrospectively added to the first Tool. Ques-
tionswerematchedwith the same ormost similar question or
series of questions from the revised Tool resulting in the in-
clusion of 91 questions totalling 136 points (Table 1). Excluding
the BMBL category, the pairing resulted in an 89.5% concor-
dance between the Tools. Concordance was calculated by
determining the percentage of the total number of points
available in the first Tool over the total number of points
available in the revised Tool (136 points/152 points 100). The
BMBL category, which consisted of one question (totalling
nine points), was excluded when calculating concordance
because the first Tool did not contain equivalent questions.Validation of the quantitative analysis systems
Retrospectively points were assigned manually for each
assessment using the first Tool, summed and totalled to
calculate percentages by category to compare two assess-
ments from a country. Raw data from the assessments were
examined to verify results, match scores and confirm that
changes observed between assessments were due to changes
in laboratory performance and not to an artifact of variations
between the Tools. Assessors were contacted to verify if there
was an actual change in capacity thus increasing or
decreasing the score.
Raw data from all first and second assessments were
analyzed to address discrepancies. For example, Fig. 1 depicts
one laboratory's performance over time, using data collected
in 2010 and a repeat assessment in 2013 using the revised
Tool. Responses were reviewed to ensure that the large im-
provements in the ‘NIC Criteria’ and ‘Equipment’ categories
were due to real changes. Similarly, the assessment value
decreased in the ‘Specimen’ category. The data were reviewed
to ensure that this accurately reflected a negative change inTable 1 e Total points available for quantitative framework pe




National Influenza Center Criteria 11
Laboratory Management 15
Safety 23







Biosafety in Microbiological and
Biomedical Laboratories (BMBL)
1
Total 111capacity. A similar exercisewas undertaken to understand the
gains or decreases in capacity for each laboratory that had
undergone multiple assessments.
Overall analysis of the results from related questions in
the Tools demonstrated that the quantitative framework
for both versions were compatible for comparison purposes.
The review indicated that changes in scores consistently re-
flected enhanced or decreased capacity. The review process
also validated the utility of adding a quantitative analysis
component to the assessments and the benefit of establishing
a baseline from which to compare future assessments in a
standardized way.Discussion
Development of this Tool required an iterative process over
two phases. The original Tool was piloted in two countries,
fine-tuned and finalized with minimal changes. The Tool was
widely used in 37 cooperative agreement and partner coun-
tries for two years (2010 and 2011). The second phase used
feedback from assessors (who used the Tool during 2010 and
2011) to increase the Tool's usability and prepare for the
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such a tool through pilot testing, feedback and review of
the assessment data. SMEs with relevant laboratory and sur-
veillance knowledge were critical in identifying key criteria to
measure a laboratory's capacity. However, the diversity of
individual expertise presented some challenges when using
team consensus for the overall Tool. We found that it may be
helpful to engage the SMEs differently to better utilize their
skills (e.g. virus isolation SMEs review only the virology cate-
gory) and thus reduce the time necessary to reach consensus.
The inclusion of monitoring and evaluation SMEs was very
helpful for developing the quantitative framework because
they provided a unique perspective, expertise in measure-
ment and the benefit of impartiality. Overall, input from a
variety of SMEs created a Tool and framework tailored to the
specific needs and goals of the project.
While the improved usability and specificity of information
was deemed a priority, limiting the revisions would have
increased the compatibility between versions of the Tool for
subsequent quantitative analysis. Small changes in the
wording of questions could change interpretation, leading to
different answers between the two versions when, in fact, the
laboratory practice was the same. Additionally, because the
first Tool was created without quantitative analysis in mind
numerous open-ended questions made application of a point
system challenging. A major lesson learnt was that devel-
oping a quantitative analysis system earlier in the process
would have eliminated or reduced the challenges of retro-
spectively analyzing data.
One of the main goals in the creation of the Tool was to
providea standardizedapproachtoassessments. It is, however,
impossible to rule out some inter-assessor variability, particu-
larly for questions where determining the acceptability of lab-
oratory practices is judged by the assessor. Although trainingFig. 2 e International Influenza Laboratory Cwas initially provided to the assessors, feedback indicated that
on-going periodic training on the Tool was needed to improve
andmaintain theconsistencyof assessments.Asa result of this
feedback written guidelines and criteria for assessors were
developed to aid in interpreting responses to open-ended
questions. Prior to conducting assessments, training is
requiredof all prospective assessors to assureunderstanding of
the guidelines and assessment criteria and ensure complete-
ness of assessments. Inter-rater reliability exercises have also
been incorporated into the trainings.
As of August 2014, 61 assessments using the Tool have
been completed in 56 cooperative agreement and partner
countries (Fig. 2). Assessors have documented laboratories'
capabilities and capacities across a variety of functions and
activities for influenza laboratory surveillance.
Conclusion
On-site laboratory assessments serve to guide national influ-
enza laboratories to build and improve influenza testing ca-
pacity to achieve or maintain a NIC designation. Since its
inception, use of the Tool provides a standardized method
for measuring laboratories' capacity, determining strengths,
generating recommendations for improvement and
measuring changes over time. The information and the
quantitative analysis generated from the Tool can be used to
document the capacities required of WHO NICs and for
meeting IHR 2005 requirements as well as to help strategically
target funds and improvements to influenza surveillance
systems. Aggregated data can be used to characterize regional
and global influenza laboratory surveillance and inform the
development of region-specific laboratory training courses.
The collaboration between APHL and CDC for creating and
implementing the Tool has been beneficial and the inclusionapacity Review: completed assessments.
p u b l i c h e a l t h 1 3 0 ( 2 0 1 6 ) 7 2e7 7 77of multiple SMEs in developing and updating both its content
and structure has been highly productive. The process
described here to develop a quantitative assessment tool
could be used as a model for other public health program
areas seeking to strengthen laboratory or other systems
capacity.
All future on-site assessments will be conducted using the
revised Tool allowing for direct comparison between assess-
ments and monitoring capacity over time. On-going results
will continue to assist countries to identify strengths and
areas for improvement, thereby enhancing laboratory capac-
ity for global influenza surveillance.Author statements
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